Scientific poster: Developing protein: Protein Interaction (PPI) assays with AlphaLISA and LANCE TR-FRET
Posted: 2 January 2018 | Catherine Lautenschlager (PerkinElmer), Daniel Cardillo (PerkinElmer), Matthew Reuter (PerkinElmer) | No comments yet
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
Protein: protein interactions (PPIs) are central to the molecular processes that take place within a cell, as the function of any given protein is often regulated by other proteins. In recent years, modulation of PPIs has received increased attention in the scientific community as a whole, and specifically within the realm of drug discovery. PPIs are being studied as therapeutic targets in a variety of diseases including cancer, cardiovascular disease, and even HIV.
Currently, there are a variety of methods used to detect PPIs, each with its own strengths and weaknesses. This is especially true in regards to sensitivity and specificity. However, the ideal assay is a cell-based, homogenous assay that maintains both its specificity and sensitivity.
Here we show that both the AlphaLISA and LANCE TR-FRET technologies allow for the development of protein: protein interaction assays in cell-based, homogenous no-wash formats suitable to HTS applications.
This scientific poster is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related content from this organisation
- Global high-content screening market set to be worth $2.52bn by 2030
- Assays for protein degradation therapeutics to accelerate undruggable proteome discoveries
- Lab automation market set to increase at CAGR of seven percent
- Brochure: Biologics workflow solutions brochure
- Brochure: Viral research solutions
Related topics
Assays, Cell-based assays, Drug Discovery Processes, Molecular Targets, Protein, Screening, Target Validation, Technology, Therapeutics
Related organisations
PerkinElmer